Table 1.
Baseline characteristics of the surgical and control groups.
| Surgical group (n = 16) | Control group (n = 16) | |
|---|---|---|
| Age, y, mean (SD) | 51 (10.5) | 48.2 (12.2) |
| Gender F-M | 15-1 | 13-3 |
| BMI, kg/m2, mean (SD) | 45 (4.7) | 43.6 (3.7) |
| Type of MS | ||
| Relapsing remitting (RRMS) | 11 | 15 |
| Secondary progressive (SPMS) | 2 | 1 |
| Primary progressive (PPMS) | 3 | 0 |
| Medications | ||
| Dalfampridinea use | 1 | 2 |
| Corticosteroids | 0 | 0 |
| Glatiramir | 5 | — |
| Interferon beta-1a | 5 | — |
| Natalizumab | 2 | — |
| Disease duration, years, mean (SD) | 15.6 (11.5) | 9 (4.3) |
| Length of follow-up, months, mean (SD) | 41.2 (28) | 39.8 (7) |
| Number of acute MS exacerbationsb | 2 | 4 |
aIndicated to help improve walking in adults with MS.
bExacerbations calculated over length of follow-up period noted in table.